GenomeFrontier Therapeutics, Inc.
- Biotech or pharma, therapeutic R&D
GenomeFrontier (GF) is actively seeking strategic partnerships to co-develop next-generation, accessible multiplex gene therapies.
GF develops advanced, affordable, virus-free gene and cell therapies using its proprietary Quantum Engine™. This platform integrates four core technologies: Quantum pBac™ (high-capacity gene integration), GTailor™ (gene design and screening), Quantum Nufect™ (gentle gene delivery), and iCellar™ (robust cell expansion). The first implementation of the Quantum Engine™ is the qCART™ process for production of next-generation CAR-T therapies that are ideal for treating both blood and solid tumors. GF’s pipeline includes virus-free CAR-T therapies with multiplex gene designs, enriched TSCM cells, strong expansion, and reduced exhaustion: GF-CART01 (B cell cancers), GF-CART02 (multiple myeloma), and GF-CART03 (solid tumors). GF aims to partner with others to co-develop innovative, accessible therapies.
)
)
){kind=logo}
){kind=logo}
){kind=logo}